Category: Science


Artificial Intelligence and Imaging in Melanoma Care: An Update

13 November 2023 In Allies & Partnerships, Events, Prevention, Science, Treatment

An early melanoma diagnosis is more likely to have a positive outcome than one diagnosed later. That’s a fact, but patients often delay having skin lesions checked for a variety of reasons, including long wait times to see a dermatologist—if they can even find one close by.

Read More


A Message from Our CEO on Veterans Day

By Marc Hurlbert, PhD, MRA Chief Executive Officer | 11 November 2023 In Allies & Partnerships, Events, Melanoma Stories, News, Policy, Prevention, Science, Treatment

On this Veterans Day, we want to express our sincere gratitude and appreciation for the brave individuals who have served and sacrificed for our country. We also want to use today to raise awareness about the unique challenges faced by veterans when it comes to increased risk of developing melanoma,...

Read More


Melanoma Risk in the Military Community

By Renee Orcione, MRA Digital Engagement & Communications Manager | 9 November 2023 In News, Prevention, Science, Treatment

Ahead of Veterans Day, the Melanoma Research Alliance (MRA) wishes to recognize the brave individuals who have served and sacrificed for our country. As the largest private nonprofit funder of melanoma research worldwide, we are keenly aware of the important intersection between military service and melanoma.

Read More


What Melanoma Patients Need to Know about Hepzato Kit

By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 23 October 2023 In News, Science, Treatment

You may have heard of Hepzato Kit, also known as Liver-Directed Melphalan, the first liver-directed therapy available for patients with metastatic uveal melanoma who have liver metastases that cannot be surgically removed.

Read More


Adjuvant Therapy: Is More Better or is Less More?

19 October 2023 In Allies & Partnerships, Events, Science, Treatment

In 2021 and 2023, the FDA expanded approval of Keytruda and Opdivo, respectively, in the adjuvant setting to include more patients with melanoma — expanding therapeutic options for a greater number of patients. These decision have created tectonic shifts in the field—opening a range of not only treatment options but also discussion points to which the medical, research, and advocacy community are split.

Read More


Advancing Research after a Rare Diagnosis: Janet Yannelli's Acral Melanoma Journey

By Renee Orcione, MRA Digital Engagement & Communications Manager | 16 October 2023 In Allies & Partnerships, Melanoma Stories, Science, Treatment

“I had never heard of acral melanoma, even though I’m a nurse,” remarked Janet Yannelli, lifelong Maine resident. Acral melanoma is a rare melanoma subtype that accounts for about 1-3% of cases each year. Acral melanoma forms on the palms, soles of feet, or under nails.

Read More


MRA Statement on Expanded Approval of Nivolumab to Patients with Stage 2 Disease

13 October 2023 In News, Science, Treatment

The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, welcomes the U.S. Food and Drug Administration (FDA) decision to expand eligibility of Bristol Myers Squibb’s Opdivo (nivolumab) to include patients with completely resected Stage IIB and IIC melanoma.

Read More


A Message from Our CEO on Rare Cancer Day

By Marc Hurlbert, PhD, MRA Chief Executive Officer | 30 September 2023 In Melanoma Stories, News, Science

Acral, mucosal, pediatric, and uveal melanomas – what we collectively call rare melanomas – represent an area of profound unmet medical need. Learn what MRA is doing to accelerate research focused on rare melanomas.

Read More


Dr. Hussein Tawbi: Opdualag Clinical Trial Updates

By Tanisha Jackson, PhD - MRA Scientific Program Director | 18 September 2023 In Allies & Partnerships, Events, News, Science, Treatment

In March of 2022, the melanoma community celebrated the FDA approval of nivolumab + relatlimab (brand name Opdualag), a new treatment for patients with metastatic melanoma that combines two different immunotherapies, nivolumab and relatlimab, into one medicine.

Read More


Combating Melanoma Brain Metastases and Leptomeningeal Disease

8 September 2023 In Allies & Partnerships, Events, Policy, Science, Treatment

Melanoma is the third most common source of brain metastases, exceeded only by lung and breast cancer. In addition, metastatic melanoma cells have the highest propensity for settling in the brain out of any solid tumor.

Read More


Login

×